Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis (MMFSSC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03678987|
Recruitment Status : Completed
First Posted : September 20, 2018
Last Update Posted : March 13, 2020
Information provided by (Responsible Party):
Kristofer Andreasson, Region Skane
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||January 1, 2020|
|Actual Study Completion Date :||February 1, 2020|
Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23.
McCune WJ, Al Abbas M. Mycophenolate mofetil, for rheumatic diseases: should we monitor the area under the curve? Curr Opin Rheumatol. 2018 May;30(3):229-230. doi: 10.1097/BOR.0000000000000501.
Abd Rahman AN, Tett SE, Staatz CE. How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease? Clin Pharmacokinet. 2014 Mar;53(3):227-245. doi: 10.1007/s40262-013-0124-z. Review.